lonafarnib has been researched along with cgp 12177 in 1 studies
Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (cgp 12177) | Trials (cgp 12177) | Recent Studies (post-2010) (cgp 12177) |
---|---|---|---|---|---|
224 | 34 | 90 | 556 | 9 | 24 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Kinsella, BT; O'Meara, SJ | 1 |
1 other study(ies) available for lonafarnib and cgp 12177
Article | Year |
---|---|
The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.
Topics: Adrenergic beta-Agonists; Alkyl and Aryl Transferases; Amino Acid Motifs; Animals; Calcium Signaling; Carrier Proteins; Cell Line; Cell Line, Tumor; Cyclic AMP; Dose-Response Relationship, Drug; Endocytosis; Epoprostenol; Farnesyltranstransferase; Heat-Shock Proteins; HSP40 Heat-Shock Proteins; Humans; Iloprost; Isoproterenol; Kidney; Leukemia, Erythroblastic, Acute; Mice; Mutagenesis, Site-Directed; Organophosphorus Compounds; Piperidines; Proline; Propanolamines; Protein Prenylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins p21(ras); Pyridines; Receptors, Adrenergic, beta-2; Receptors, Epoprostenol; Receptors, Thromboxane A2, Prostaglandin H2; Recombinant Fusion Proteins; Signal Transduction; Transfection | 2005 |